Period,symbol,NAV,sharesOutstanding,researchDevelopment,effectOfAccountingCharges,incomeBeforeTax,minorityInterest,netIncome,sellingGeneralAdministrative,grossProfit,ebit,operatingIncome,otherOperatingExpenses,interestExpense,extraordinaryItems,nonRecurring,otherItems,incomeTaxExpense,totalRevenue,totalOperatingExpenses,costOfRevenue,totalOtherIncomeExpenseNet,discontinuedOperations,netIncomeFromContinuingOps,netIncomeApplicableToCommonShares,capitalSurplus,totalLiab,totalStockholderEquity,otherCurrentLiab,totalAssets,commonStock,otherCurrentAssets,retainedEarnings,otherLiab,treasuryStock,cash,totalCurrentLiabilities,shortLongTermDebt,otherStockholderEquity,propertyPlantEquipment,totalCurrentAssets,shortTermInvestments,netReceivables,longTermDebt,inventory,accountsPayable,investments,changeToLiabilities,totalCashflowsFromInvestingActivities,netBorrowings,totalCashFromFinancingActivities,changeToOperatingActivities,issuanceOfStock,changeInCash,totalCashFromOperatingActivities,depreciation,changeToInventory,changeToAccountReceivables,otherCashflowsFromFinancingActivities,changeToNetincome,capitalExpenditures,WC,language,region,quoteType,triggerable,quoteSourceName,currency,earningsTimestamp,earningsTimestampStart,earningsTimestampEnd,epsTrailingTwelveMonths,epsForward,epsCurrentYear,priceEpsCurrentYear,bookValue,fiftyDayAverage,fiftyDayAverageChange,fiftyDayAverageChangePercent,twoHundredDayAverage,twoHundredDayAverageChange,twoHundredDayAverageChangePercent,marketCap,forwardPE,priceToBook,sourceInterval,exchangeTimezoneName,exchangeTimezoneShortName,gmtOffSetMilliseconds,priceHint,postMarketChangePercent,postMarketTime,postMarketPrice,postMarketChange,regularMarketChangePercent,regularMarketDayRange,regularMarketPreviousClose,bid,ask,bidSize,askSize,messageBoardId,marketState,shortName,market,exchangeDataDelayedBy,exchange,esgPopulated,tradeable,regularMarketPrice,regularMarketTime,regularMarketChange,regularMarketOpen,regularMarketDayHigh,regularMarketDayLow,regularMarketVolume,fullExchangeName,longName,financialCurrency,averageDailyVolume3Month,averageDailyVolume10Day,fiftyTwoWeekLowChange,fiftyTwoWeekLowChangePercent,fiftyTwoWeekRange,fiftyTwoWeekHighChange,fiftyTwoWeekHighChangePercent,fiftyTwoWeekLow,fiftyTwoWeekHigh,Beta (5Y Monthly),52-Week Change 3,S&P500 52-Week Change 3,52 Week High 3,52 Week Low 3,50-Day Moving Average 3,200-Day Moving Average 3,Avg Vol (3 month) 3,Avg Vol (10 day) 3,Shares Outstanding 5,Implied Shares Outstanding 6,Float,% Held by Insiders 1,% Held by Institutions 1,"Shares Short (Jun 14, 2021) 4","Short Ratio (Jun 14, 2021) 4","Short % of Float (Jun 14, 2021) 4","Short % of Shares Outstanding (Jun 14, 2021) 4","Shares Short (prior month May 13, 2021) 4",Forward Annual Dividend Rate 4,Forward Annual Dividend Yield 4,Trailing Annual Dividend Rate 3,Trailing Annual Dividend Yield 3,5 Year Average Dividend Yield 4,Payout Ratio 4,Dividend Date 3,Ex-Dividend Date 4,Last Split Factor 2,Last Split Date 3,Fiscal Year Ends,Most Recent Quarter (mrq),Profit Margin,Operating Margin (ttm),Return on Assets (ttm),Return on Equity (ttm),Revenue (ttm),Revenue Per Share (ttm),Quarterly Revenue Growth (yoy),Gross Profit (ttm),EBITDA,Net Income Avi to Common (ttm),Diluted EPS (ttm),Quarterly Earnings Growth (yoy),Total Cash (mrq),Total Cash Per Share (mrq),Total Debt (mrq),Total Debt/Equity (mrq),Current Ratio (mrq),Book Value Per Share (mrq),Operating Cash Flow (ttm),Levered Free Cash Flow (ttm),index,zip,sector,fullTimeEmployees,compensationRisk,auditRisk,longBusinessSummary,city,phone,state,shareHolderRightsRisk,compensationAsOfEpochDate,governanceEpochDate,boardRisk,country,website,maxAge,overallRisk,address1,fax,industry,address2
t0,FLXN,-38867000,49942100,14047000,,-28556000,,-28556000,27660000,18566000,-23141000,-23141000,,-5189000,,,,0,24589000,47730000,6023000,-5415000,,-28556000,-28556000,771954000,269246000,-38867000,15021000,230379000,50000,444000,-810861000,489000,-10000,98707000,57982000,18333000,-10000,25757000,204622000,55686000,30669000,205029000,12676000,6650000,11750000,124000,10949000,-3055000,-1472000,-976000,1708000,-8997000,-18474000,951000,2178000,-340000,-125000,5660000,-801000,146640000,en-US,US,EQUITY,True,Nasdaq Real Time Price,USD,1620849600,1628020800,1628539200,-2.205,-0.76,-1.77,-3.480226,-0.778,5.925833,0.23416662,0.039516237,8.347754,-2.1877537,-0.26207694,307643328,-8.105263,-7.9177375,15,America/New_York,EDT,-14400000,2,0.0,1630528946,6.16,0.0,3.0100307,5.975 - 6.3399,5.98,6.0,6.16,31,13,finmb_61177529,POST,"Flexion Therapeutics, Inc.",us_market,0,NGM,False,False,6.16,1630526403,0.17999983,6.04,6.3399,5.975,1703603,NasdaqGM,"Flexion Therapeutics, Inc.",USD,797521,1461350,1.8599997,0.43255803,4.3 - 13.66,-7.5,-0.5490483,4.3,13.66,1.4,,,13.66,4.3,5.93,8.35,797.52k,1.46M,49.94M,,45.04M,3.70%,89.50%,6.51M,14.38,13.65%,13.04%,7.17M,,,,,,0.00%,,,,,"Dec 30, 2020","Mar 30, 2021",-117.16%,-92.85%,-24.02%,,90.01M,1.88,22.20%,66.53M,-81.56M,-105.46M,-2.20,,154.39M,3.09,230.65M,,3.53,-0.78,-60.84M,-28.93M,Value,01803,Healthcare,257,8,6,"Flexion Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for the treatment of patients with musculoskeletal conditions in the United States. The company offers ZILRETTA, an intra-articular injection for the management of osteoarthritis (OA) knee pain. It is also involved in the development of FX201, a gene therapy product candidate designed to provide on demand production of an anti-inflammatory protein, interleukin-1 receptor antagonist for pain relief from OA of the knee; and FX301, a NaV1.7 inhibitor for the management of post-operative pain. The company was founded in 2007 and is headquartered in Burlington, Massachusetts.",Burlington,781 305 7777,MA,8,1609372800,1622505600,7,United States,http://www.flexiontherapeutics.com,86400,8,10 Mall Road,781 202 3399,Drug Manufacturers—Specialty & Generic,Suite 301
t-1,FLXN,-16660000,49942100,10593000,,-19647000,,-19647000,23714000,20007000,-14300000,-14300000,,-5179000,,,,0,26310000,40610000,6303000,-5347000,,-19647000,-19647000,765607000,268586000,-16660000,13685000,251926000,49000,408000,-782305000,295000,-11000,107704000,55268000,16806000,-11000,26115000,225811000,67688000,30271000,206900000,15394000,6928000,-10901000,133000,-12098000,-3055000,907000,533000,907000,-20933000,-9742000,823000,141000,-2126000,-125000,7975000,-1209000,170543000,en-US,US,EQUITY,True,Nasdaq Real Time Price,USD,1620849600,1628020800,1628539200,-2.205,-0.76,-1.77,-3.480226,-0.778,5.925833,0.23416662,0.039516237,8.347754,-2.1877537,-0.26207694,307643328,-8.105263,-7.9177375,15,America/New_York,EDT,-14400000,2,0.0,1630528946,6.16,0.0,3.0100307,5.975 - 6.3399,5.98,6.0,6.16,31,13,finmb_61177529,POST,"Flexion Therapeutics, Inc.",us_market,0,NGM,False,False,6.16,1630526403,0.17999983,6.04,6.3399,5.975,1703603,NasdaqGM,"Flexion Therapeutics, Inc.",USD,797521,1461350,1.8599997,0.43255803,4.3 - 13.66,-7.5,-0.5490483,4.3,13.66,1.4,,,13.66,4.3,5.93,8.35,797.52k,1.46M,49.94M,,45.04M,3.70%,89.50%,6.51M,14.38,13.65%,13.04%,7.17M,,,,,,0.00%,,,,,"Dec 30, 2020","Mar 30, 2021",-117.16%,-92.85%,-24.02%,,90.01M,1.88,22.20%,66.53M,-81.56M,-105.46M,-2.20,,154.39M,3.09,230.65M,,3.53,-0.78,-60.84M,-28.93M,Value,01803,Healthcare,257,8,6,"Flexion Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for the treatment of patients with musculoskeletal conditions in the United States. The company offers ZILRETTA, an intra-articular injection for the management of osteoarthritis (OA) knee pain. It is also involved in the development of FX201, a gene therapy product candidate designed to provide on demand production of an anti-inflammatory protein, interleukin-1 receptor antagonist for pain relief from OA of the knee; and FX301, a NaV1.7 inhibitor for the management of post-operative pain. The company was founded in 2007 and is headquartered in Burlington, Massachusetts.",Burlington,781 305 7777,MA,8,1609372800,1622505600,7,United States,http://www.flexiontherapeutics.com,86400,8,10 Mall Road,781 202 3399,Drug Manufacturers—Specialty & Generic,Suite 301
t-2,FLXN,-3095000,49942100,10092000,,-24390000,,-24638000,27370000,18592000,-18870000,-18870000,,-5125000,,,,248000,23664000,42534000,5072000,-5520000,,-24638000,-24638000,759520000,266462000,-3095000,13193000,263367000,49000,400000,-762658000,295000,-6000,128637000,50878000,12222000,-6000,26302000,237065000,56770000,28111000,208832000,17953000,7233000,-38726000,5847000,-42035000,-3055000,-215000,3484000,78000,-54462000,-12212000,959000,1439000,-6375000,-293000,4702000,-3322000,186187000,en-US,US,EQUITY,True,Nasdaq Real Time Price,USD,1620849600,1628020800,1628539200,-2.205,-0.76,-1.77,-3.480226,-0.778,5.925833,0.23416662,0.039516237,8.347754,-2.1877537,-0.26207694,307643328,-8.105263,-7.9177375,15,America/New_York,EDT,-14400000,2,0.0,1630528946,6.16,0.0,3.0100307,5.975 - 6.3399,5.98,6.0,6.16,31,13,finmb_61177529,POST,"Flexion Therapeutics, Inc.",us_market,0,NGM,False,False,6.16,1630526403,0.17999983,6.04,6.3399,5.975,1703603,NasdaqGM,"Flexion Therapeutics, Inc.",USD,797521,1461350,1.8599997,0.43255803,4.3 - 13.66,-7.5,-0.5490483,4.3,13.66,1.4,,,13.66,4.3,5.93,8.35,797.52k,1.46M,49.94M,,45.04M,3.70%,89.50%,6.51M,14.38,13.65%,13.04%,7.17M,,,,,,0.00%,,,,,"Dec 30, 2020","Mar 30, 2021",-117.16%,-92.85%,-24.02%,,90.01M,1.88,22.20%,66.53M,-81.56M,-105.46M,-2.20,,154.39M,3.09,230.65M,,3.53,-0.78,-60.84M,-28.93M,Value,01803,Healthcare,257,8,6,"Flexion Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for the treatment of patients with musculoskeletal conditions in the United States. The company offers ZILRETTA, an intra-articular injection for the management of osteoarthritis (OA) knee pain. It is also involved in the development of FX201, a gene therapy product candidate designed to provide on demand production of an anti-inflammatory protein, interleukin-1 receptor antagonist for pain relief from OA of the knee; and FX301, a NaV1.7 inhibitor for the management of post-operative pain. The company was founded in 2007 and is headquartered in Burlington, Massachusetts.",Burlington,781 305 7777,MA,8,1609372800,1622505600,7,United States,http://www.flexiontherapeutics.com,86400,8,10 Mall Road,781 202 3399,Drug Manufacturers—Specialty & Generic,Suite 301
t-3,FLXN,16515000,49942100,12507000,,-32371000,,-32619000,24785000,10025000,-27267000,-27267000,,-5002000,,,,248000,15451000,42718000,5426000,-5104000,,-32619000,-32619000,754483000,255261000,16515000,7416000,271776000,49000,200000,-738020000,295000,3000,183099000,37357000,7639000,3000,25209000,246567000,17570000,21606000,210819000,19392000,7886000,-4290000,495000,-6584000,-3055000,98074000,-4962000,98181000,71080000,-20410000,961000,599000,8838000,-107000,3963000,-2294000,209210000,en-US,US,EQUITY,True,Nasdaq Real Time Price,USD,1620849600,1628020800,1628539200,-2.205,-0.76,-1.77,-3.480226,-0.778,5.925833,0.23416662,0.039516237,8.347754,-2.1877537,-0.26207694,307643328,-8.105263,-7.9177375,15,America/New_York,EDT,-14400000,2,0.0,1630528946,6.16,0.0,3.0100307,5.975 - 6.3399,5.98,6.0,6.16,31,13,finmb_61177529,POST,"Flexion Therapeutics, Inc.",us_market,0,NGM,False,False,6.16,1630526403,0.17999983,6.04,6.3399,5.975,1703603,NasdaqGM,"Flexion Therapeutics, Inc.",USD,797521,1461350,1.8599997,0.43255803,4.3 - 13.66,-7.5,-0.5490483,4.3,13.66,1.4,,,13.66,4.3,5.93,8.35,797.52k,1.46M,49.94M,,45.04M,3.70%,89.50%,6.51M,14.38,13.65%,13.04%,7.17M,,,,,,0.00%,,,,,"Dec 30, 2020","Mar 30, 2021",-117.16%,-92.85%,-24.02%,,90.01M,1.88,22.20%,66.53M,-81.56M,-105.46M,-2.20,,154.39M,3.09,230.65M,,3.53,-0.78,-60.84M,-28.93M,Value,01803,Healthcare,257,8,6,"Flexion Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for the treatment of patients with musculoskeletal conditions in the United States. The company offers ZILRETTA, an intra-articular injection for the management of osteoarthritis (OA) knee pain. It is also involved in the development of FX201, a gene therapy product candidate designed to provide on demand production of an anti-inflammatory protein, interleukin-1 receptor antagonist for pain relief from OA of the knee; and FX301, a NaV1.7 inhibitor for the management of post-operative pain. The company was founded in 2007 and is headquartered in Burlington, Massachusetts.",Burlington,781 305 7777,MA,8,1609372800,1622505600,7,United States,http://www.flexiontherapeutics.com,86400,8,10 Mall Road,781 202 3399,Drug Manufacturers—Specialty & Generic,Suite 301
